SGCB and chronic thromboembolic pulmonary hypertension: The highest-cited article was published by Ghofrani et al. 2013a on the clinical trial of the sGC stimulator riociguat in the treatment of CTEPH, and the seventh highest-cited reference was also published by the same author, Ghofrani HA, which mainly evaluated the efficacy of riociguat in PAH.